JP2015534817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534817A5 JP2015534817A5 JP2015540833A JP2015540833A JP2015534817A5 JP 2015534817 A5 JP2015534817 A5 JP 2015534817A5 JP 2015540833 A JP2015540833 A JP 2015540833A JP 2015540833 A JP2015540833 A JP 2015540833A JP 2015534817 A5 JP2015534817 A5 JP 2015534817A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- protein
- gene editing
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018073676A JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721302P | 2012-11-01 | 2012-11-01 | |
| US61/721,302 | 2012-11-01 | ||
| US201361785404P | 2013-03-14 | 2013-03-14 | |
| US61/785,404 | 2013-03-14 | ||
| US201361842874P | 2013-07-03 | 2013-07-03 | |
| US61/842,874 | 2013-07-03 | ||
| PCT/US2013/068118 WO2014071219A1 (en) | 2012-11-01 | 2013-11-01 | Methods and products for expressing proteins in cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018073677A Division JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073676A Division JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534817A JP2015534817A (ja) | 2015-12-07 |
| JP2015534817A5 true JP2015534817A5 (enExample) | 2016-12-15 |
| JP6510416B2 JP6510416B2 (ja) | 2019-05-08 |
Family
ID=50628111
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540833A Active JP6510416B2 (ja) | 2012-11-01 | 2013-11-01 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073677A Active JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073676A Active JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2021027831A Active JP7436406B2 (ja) | 2012-11-01 | 2021-02-24 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2024018042A Pending JP2024056815A (ja) | 2012-11-01 | 2024-02-08 | 細胞中でタンパク質を発現するための方法および生成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018073677A Active JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073676A Active JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2021027831A Active JP7436406B2 (ja) | 2012-11-01 | 2021-02-24 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2024018042A Pending JP2024056815A (ja) | 2012-11-01 | 2024-02-08 | 細胞中でタンパク質を発現するための方法および生成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (20) | US9447395B2 (enExample) |
| EP (2) | EP3786298A1 (enExample) |
| JP (5) | JP6510416B2 (enExample) |
| KR (4) | KR20230154283A (enExample) |
| CN (1) | CN104769112A (enExample) |
| AU (3) | AU2013337651B2 (enExample) |
| BR (2) | BR122019025678B1 (enExample) |
| CA (2) | CA3150985A1 (enExample) |
| MX (2) | MX363017B (enExample) |
| RU (2) | RU2711249C2 (enExample) |
| WO (1) | WO2014071219A1 (enExample) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| HRP20250981T1 (hr) | 2011-05-24 | 2025-10-24 | BioNTech SE | Individualizirana cjepiva protiv raka |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
| JP2015529685A (ja) | 2012-09-17 | 2015-10-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ | 筋萎縮性側索硬化症の処置のための組成物および方法 |
| MX363017B (es) | 2012-11-01 | 2019-03-04 | Factor Bioscience Inc | Métodos y productos para la expresión de proteínas en células. |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| EP2925348B1 (en) | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| KR102307280B1 (ko) | 2013-06-05 | 2021-10-01 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| LT3702466T (lt) | 2013-08-27 | 2023-02-27 | Research Institute At Nationwide Children's Hospital | Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JP2016538276A (ja) | 2013-11-05 | 2016-12-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔ Ｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ | 筋萎縮性側索硬化症の処置のためのＮＦ−κＢおよびＳＯＤ−１を阻害する組成物および方法 |
| JP2016536021A (ja) | 2013-11-07 | 2016-11-24 | エディタス・メディシン，インコーポレイテッド | ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| AU2015229299A1 (en) * | 2014-03-12 | 2016-09-22 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| US10280419B2 (en) | 2014-05-09 | 2019-05-07 | UNIVERSITé LAVAL | Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| EP3197269A1 (en) | 2014-09-26 | 2017-08-02 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| MX388527B (es) * | 2014-11-26 | 2025-03-20 | Huvepharma Inc | Composiciones adyuvantes y metodos relacionados. |
| US10195261B2 (en) | 2014-11-26 | 2019-02-05 | VaxLiant, LLC | Adjuvant compositions and related methods |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3543339A1 (en) * | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| MX390860B (es) | 2015-03-24 | 2025-03-21 | Huvepharma Inc | Composiciones adyuvantes y metodos relacionados. |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| US10676735B2 (en) | 2015-07-22 | 2020-06-09 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
| ES2948559T3 (es) * | 2015-07-25 | 2023-09-14 | Habib Frost | Un sistema, un dispositivo y un método para proporcionar una terapia o una cura para el cáncer y otros estados patológicos |
| CN108351350B (zh) | 2015-08-25 | 2022-02-18 | 杜克大学 | 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
| ES2914225T3 (es) | 2015-10-16 | 2022-06-08 | Modernatx Inc | Análogos de cap de ARNm con enlace de fosfato modificado |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| EP4434589A3 (en) | 2015-10-23 | 2025-05-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
| EP3384038B1 (en) * | 2015-11-23 | 2024-07-24 | The Regents of The University of Colorado, A Body Corporate | Methods and compositions for reprogramming cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| CN105494263B (zh) * | 2015-12-25 | 2018-11-30 | 哈尔滨医科大学 | 一种产生ho-1/app/psen1三转基因阿尔茨海默病小鼠模型的方法 |
| EP3411078A1 (en) * | 2016-02-02 | 2018-12-12 | Crispr Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| WO2017141109A1 (en) * | 2016-02-18 | 2017-08-24 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| WO2017147278A1 (en) | 2016-02-25 | 2017-08-31 | The Children's Medical Center Corporation | Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology |
| US11083799B2 (en) | 2016-03-16 | 2021-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
| CN109154001B (zh) * | 2016-03-31 | 2023-07-18 | 埃泽瑞斯公司 | Utr序列 |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| US12065667B2 (en) | 2016-04-16 | 2024-08-20 | Ohio State Innovation Foundation | Modified Cpf1 MRNA, modified guide RNA, and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| AU2017295720B2 (en) | 2016-07-13 | 2021-07-22 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| CA3033788A1 (en) * | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN106370765A (zh) * | 2016-08-23 | 2017-02-01 | 国家烟草质量监督检验中心 | 一种基于反相色谱飞行时间质谱的喉癌尿液差异代谢物的测定筛选方法 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN106381310B (zh) * | 2016-08-31 | 2020-02-04 | 武汉华美生物工程有限公司 | 一种用t7噬菌体rna聚合酶和t7启动子系统在哺乳动物细胞表达蛋白的方法 |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| EP3538075A4 (en) * | 2016-11-11 | 2020-08-05 | Dnalite Therapeutics, Inc. | GENE THERAPY STRUCTURES AND PROCESSES |
| KR101908593B1 (ko) * | 2016-12-07 | 2018-10-16 | 연세대학교 산학협력단 | Cftr 유전자 소실 유도 가이드 rna, cftr 변이를 갖는 t84 세포 및 이의 용도 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US20200040061A1 (en) * | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| US11168319B1 (en) * | 2017-02-28 | 2021-11-09 | Inari Agriculture Technology, Inc. | Plant cell culture |
| WO2018160592A1 (en) * | 2017-02-28 | 2018-09-07 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CN107475255B (zh) * | 2017-03-21 | 2021-03-26 | 河北医科大学第二医院 | 一种基因载体介导的基于CRISPR/Cas9基因编辑系统的sgRNA及其用途 |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| WO2018227432A1 (en) * | 2017-06-14 | 2018-12-20 | Wuhan Institute Of Virology, Chinese Academy Of Sciences | Cd2-associated protein (cd2ap) and its interactive proteins |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| WO2019144124A1 (en) | 2018-01-22 | 2019-07-25 | Inari Agriculture, Inc. | Plant gene editing systems, methods, and compositions |
| EP3775202A4 (en) * | 2018-03-27 | 2022-04-06 | Factor Bioscience Inc. | NUCLEIC ACID BASED THERAPEUTICS |
| CA3097648A1 (en) | 2018-04-18 | 2019-10-24 | Altius Institute For Biomedical Sciences | Animal pathogen-derived polypeptides and uses thereof for genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN108624592B (zh) * | 2018-05-24 | 2021-08-17 | 苏州大学张家港工业技术研究院 | 针对DJ-1基因编辑的sgRNA筛选及其载体与应用 |
| US12264181B2 (en) | 2018-06-27 | 2025-04-01 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
| EP3813848A4 (en) * | 2018-06-27 | 2022-07-20 | ModernaTX, Inc. | EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| CN108949830B (zh) * | 2018-08-03 | 2021-11-26 | 福州大学 | 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN109628404B (zh) * | 2018-12-18 | 2020-04-28 | 浙江大学 | 猪皮下脂肪前体细胞永生化细胞系的构建方法及用途 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110200973A (zh) * | 2019-06-19 | 2019-09-06 | 南京市儿童医院 | Dna依赖性蛋白激酶特异性抑制剂在制备防治肾纤维化药物中的用途 |
| US12344572B2 (en) | 2019-07-03 | 2025-07-01 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| US11746354B2 (en) | 2019-07-19 | 2023-09-05 | Inari Agriculture Technology, Inc. | Homology dependent repair genome editing |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN110699381A (zh) * | 2019-09-17 | 2020-01-17 | 合肥瑞灵生物科技有限公司 | 地中海贫血病基因治疗载体构建方法及其用途 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021191678A1 (en) | 2020-03-23 | 2021-09-30 | Avectas Limited | Engineering of dendritic cells for generation of vaccines against sars-cov-2 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN113151181B (zh) * | 2021-04-14 | 2022-11-29 | 中山大学附属第七医院(深圳) | 一种脂肪干细胞重编程为神经元的方法及负载该神经元的细胞适应性水凝胶修复脊髓损伤 |
| CN113373214B (zh) * | 2021-06-18 | 2024-03-29 | 中国人民解放军军事科学院军事医学研究院 | Cd30在诊断脑神经相关疾病中的用途 |
| WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
| CN114150017B (zh) * | 2021-11-30 | 2023-05-16 | 长江大学 | 一种调节猪未成熟睾丸支持细胞乳酸分泌水平的方法及应用 |
| EP4544051A2 (en) | 2022-06-24 | 2025-04-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
| WO2024032678A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| WO2025084896A1 (ko) * | 2023-10-18 | 2025-04-24 | 연세대학교 산학협력단 | 신경세포 분화 유도용 재조합 벡터 및 이를 포함하는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 |
| CN118667815B (zh) * | 2024-07-16 | 2025-02-14 | 宁夏大学 | 一种靶向prdm1改善牛子宫内膜炎的核苷酸序列及其应用 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539465A (en) | 1968-10-08 | 1970-11-10 | Ncr Co | Encapsulation of hydrophilic liquid-in-oil emulsions |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| AU5734998A (en) | 1997-01-10 | 1998-08-03 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| AU9319398A (en) | 1997-09-19 | 1999-04-05 | Sequitur, Inc. | Sense mrna therapy |
| US20110171185A1 (en) | 1999-06-30 | 2011-07-14 | Klimanskaya Irina V | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| AU2002313817A1 (en) | 2001-08-27 | 2003-03-10 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| EP1437403A4 (en) | 2001-09-21 | 2004-10-27 | Japan Science & Tech Corp | METHOD FOR PATTERNING REPROGRAMMING FACTOR, METHOD OF PATTERNED REPROGRAMMING FACTOR, METHOD FOR USE OF REPROGRAMMING FACTOR, METHOD FOR DIFFERENTIATING AND SIFE-INGENATING FAN |
| WO2003033697A1 (en) | 2001-10-18 | 2003-04-24 | Ixion Biotechnology, Inc. | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| BRPI0410886A (pt) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| NZ553235A (en) | 2004-09-08 | 2009-11-27 | Wisconsin Alumni Res Found | Culturing human pluripotent stem cells |
| CN101052712A (zh) | 2004-09-08 | 2007-10-10 | 威斯康星校友研究基金会 | 培养人胚胎干细胞 |
| CN103172747A (zh) * | 2005-01-25 | 2013-06-26 | 细胞治疗学公司 | 体内半衰期改变的生物活性蛋白质偶联物 |
| JP5147692B2 (ja) * | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| EP1913149A4 (en) * | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| US20090263900A1 (en) * | 2008-04-14 | 2009-10-22 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| CN101356270B (zh) | 2005-12-13 | 2014-02-12 | 国立大学法人京都大学 | 核重新编程因子 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| JP2009520714A (ja) | 2005-12-22 | 2009-05-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 低オクタノエート型ヒトアルブミン |
| DE102006051516A1 (de) * | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| GB0623635D0 (en) | 2006-11-27 | 2007-01-03 | Stem Cell Sciences Uk Ltd | Pluripotent cell growth media |
| AU2007333225B2 (en) | 2006-12-08 | 2014-06-12 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| US10829733B2 (en) | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| WO2008086529A2 (en) | 2007-01-11 | 2008-07-17 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| US8859229B2 (en) | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| AU2008231020B2 (en) | 2007-03-23 | 2013-09-05 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| EP2626416A3 (en) | 2007-04-07 | 2013-12-18 | The Whitehead Institute for Biomedical Research | Reprogramming of somatic cells |
| AU2008286249B2 (en) | 2007-12-10 | 2013-10-10 | Kyoto University | Efficient method for nuclear reprogramming |
| EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| WO2009117439A2 (en) | 2008-03-17 | 2009-09-24 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US20110045001A1 (en) | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| JP2011522540A (ja) | 2008-06-04 | 2011-08-04 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| WO2009147400A1 (en) | 2008-06-05 | 2009-12-10 | Iti Scotland Limited | Stem cell culture media and methods |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| US20110263015A1 (en) | 2008-08-20 | 2011-10-27 | Virxsys Corporation | Compositions and methods for generation of pluripotent stem cells |
| DK2356221T3 (en) | 2008-10-24 | 2019-02-18 | Wisconsin Alumni Res Found | Pluripotent stem cells obtained by non-viral reprogramming |
| ES2561949T3 (es) * | 2008-11-21 | 2016-03-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Reprogramación de células hacia un estado pluripotente |
| US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
| WO2010079340A2 (en) | 2009-01-08 | 2010-07-15 | Eisai R & D Management Co., Ltd. | Assay |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US8219348B2 (en) | 2009-01-22 | 2012-07-10 | Johnson Controls Technology Company | Method for calibrating and/or correcting a display device having a needle, the needle being able to move in rotation about an axis of rotation |
| WO2010093655A2 (en) | 2009-02-10 | 2010-08-19 | University Of Dayton | Enhanced method for producing stem-like cells from somatic cells |
| US10894944B2 (en) | 2009-04-10 | 2021-01-19 | Monash University | Cell culture media |
| EP2421563B1 (en) | 2009-04-22 | 2017-04-12 | Massachusetts Institute of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| US10837020B2 (en) | 2009-04-22 | 2020-11-17 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long RNA molecules |
| ES2849181T3 (es) | 2009-04-22 | 2021-08-16 | Viacyte Inc | Composiciones celulares derivadas de células reprogramadas desdiferenciadas |
| US8496941B2 (en) | 2009-06-03 | 2013-07-30 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| BR112012002291A2 (pt) * | 2009-07-31 | 2016-11-29 | Ethris Gmbh | "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos" |
| WO2011036640A2 (en) * | 2009-09-24 | 2011-03-31 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
| JP2013507974A (ja) * | 2009-10-29 | 2013-03-07 | マックマスター ユニバーシティー | 線維芽細胞からの誘導多能性幹細胞および前駆細胞の作製法 |
| US9295697B2 (en) | 2009-11-04 | 2016-03-29 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
| KR20120107088A (ko) | 2009-11-11 | 2012-09-28 | 샌포드-번햄 메디칼 리서치 인스티튜트 | ⅰＰＳ 세포들의 생산 및 조절 방법 및 그들의 조성물들 |
| US20130189741A1 (en) | 2009-12-07 | 2013-07-25 | Cellscript, Inc. | Compositions and methods for reprogramming mammalian cells |
| SI3112467T1 (en) | 2009-12-07 | 2018-06-29 | The Trustees Of The University Of Pennsylvania | Rna preparations comprising purified modified rna for reprogramming cells |
| EP3456826B1 (en) | 2009-12-10 | 2023-06-28 | Regents of the University of Minnesota | Tal effector-mediated dna modification |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| WO2011094738A1 (en) * | 2010-02-01 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced efficiency of induced pluripotent stem cell generation |
| WO2011110886A1 (en) | 2010-03-09 | 2011-09-15 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| EP2558571A4 (en) | 2010-04-16 | 2014-09-24 | Immune Disease Inst Inc | DELAYED POLYPEPTIDE EXPRESSION FROM MODIFIED SYNTHETIC RNAS AND USES THEREOF |
| US9725695B2 (en) | 2010-05-05 | 2017-08-08 | The Regents Of The University Of California | Stem cell defined media for xeno-free and feeder free conditions and uses thereof |
| US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| WO2011141820A1 (en) * | 2010-05-12 | 2011-11-17 | Cellectis | Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
| JP6208580B2 (ja) * | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| EP2392208B1 (en) * | 2010-06-07 | 2016-05-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
| EP2580331A4 (en) * | 2010-06-14 | 2013-11-27 | Univ Iowa State Res Found Inc | NUCLEASE ACTIVITY OF THE TAL EFFECTOR AND FUSION PROTEIN FOKI |
| AU2011267849B2 (en) * | 2010-06-15 | 2015-02-05 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| BR112013002811A8 (pt) | 2010-08-05 | 2020-01-28 | Wisconsin Alumni Res Found | meios básicos simplificados para cultura celular pluripotente de humano |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012021632A2 (en) * | 2010-08-10 | 2012-02-16 | The Johns Hopkins University | Generation and use of pluripotent stem cells |
| GB201014169D0 (en) * | 2010-08-25 | 2010-10-06 | Cambridge Entpr Ltd | In vitro hepatic differentiation |
| EP2616540A4 (en) | 2010-09-14 | 2014-02-19 | Univ Kyoto | METHOD FOR EFFICIENT MANUFACTURE OF INDUCED PLURIPOTENTER STEM CELLS |
| CA2811364C (en) * | 2010-09-27 | 2022-01-04 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| EP2625278A1 (en) | 2010-10-08 | 2013-08-14 | Regents of the University of Minnesota | A method to increase gene targeting frequency |
| JP5888753B2 (ja) | 2010-11-04 | 2016-03-22 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| US9267123B2 (en) * | 2011-01-05 | 2016-02-23 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| KR20120096395A (ko) * | 2011-02-22 | 2012-08-30 | 주식회사 툴젠 | 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법 |
| CA2828239C (en) * | 2011-02-25 | 2020-10-06 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| CN103502436A (zh) | 2011-03-07 | 2014-01-08 | 麻省理工学院 | 用核酸转染细胞的方法 |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| CA3111953C (en) * | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US9862926B2 (en) | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
| EP2732029B1 (en) | 2011-07-11 | 2019-01-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for cell reprogramming and genome engineering |
| CA2848417C (en) * | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| RU2624139C2 (ru) * | 2011-12-05 | 2017-06-30 | Фэктор Байосайенс Инк. | Способы и препараты для трансфекции клеток |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CA2859691A1 (en) | 2011-12-21 | 2013-06-27 | Moderna Therapeutics, Inc. | Methods of increasing the viability or longevity of an organ or organ explant |
| EP3421601B1 (en) | 2011-12-30 | 2019-12-04 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| WO2013152220A2 (en) * | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| EP2836501B1 (en) | 2012-04-10 | 2018-03-07 | City of Hope | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
| AU2013251649B2 (en) | 2012-04-24 | 2019-04-04 | Vcell Therapeutics, Inc. | Generating pluripotent cells de novo |
| US9738879B2 (en) * | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
| WO2013173248A2 (en) | 2012-05-13 | 2013-11-21 | Allele Biotechnology And Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna |
| US10119150B2 (en) | 2012-05-13 | 2018-11-06 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| US10155929B2 (en) | 2012-05-13 | 2018-12-18 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| HUE051612T2 (hu) * | 2012-07-11 | 2021-03-01 | Sangamo Therapeutics Inc | Eljárások és készítmények lizoszomális tárolási betegségek kezelésére |
| EP2684892A1 (en) * | 2012-07-13 | 2014-01-15 | Association Française contre les Myopathies | Compositions and methods for duchenne muscular dystrophy gene therapy |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| MX363017B (es) | 2012-11-01 | 2019-03-04 | Factor Bioscience Inc | Métodos y productos para la expresión de proteínas en células. |
| US20140140969A1 (en) * | 2012-11-20 | 2014-05-22 | Sangamo Biosciences, Inc. | Methods and compositions for muscular dystrophies |
| CA2892448A1 (en) * | 2012-12-05 | 2014-06-12 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of metabolic disorders |
| RU2022101438A (ru) | 2013-02-22 | 2022-02-11 | Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити | Соединения, композиции, способы и наборы, связанные с удлинением теломер |
| KR102307280B1 (ko) * | 2013-06-05 | 2021-10-01 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| CN104878020B (zh) | 2015-04-29 | 2017-09-15 | 华中农业大学 | 一种控制水稻叶片直立性发育的基因及其应用 |
| CA3033788A1 (en) * | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
-
2013
- 2013-11-01 MX MX2015005346A patent/MX363017B/es unknown
- 2013-11-01 WO PCT/US2013/068118 patent/WO2014071219A1/en not_active Ceased
- 2013-11-01 JP JP2015540833A patent/JP6510416B2/ja active Active
- 2013-11-01 KR KR1020237036946A patent/KR20230154283A/ko not_active Ceased
- 2013-11-01 CA CA3150985A patent/CA3150985A1/en active Pending
- 2013-11-01 EP EP20184168.1A patent/EP3786298A1/en not_active Withdrawn
- 2013-11-01 KR KR1020157013918A patent/KR102121086B1/ko active Active
- 2013-11-01 KR KR1020217033133A patent/KR102596302B1/ko active Active
- 2013-11-01 EP EP13850281.0A patent/EP2914728B1/en active Active
- 2013-11-01 BR BR122019025678-0A patent/BR122019025678B1/pt active IP Right Grant
- 2013-11-01 RU RU2015120524A patent/RU2711249C2/ru active
- 2013-11-01 CA CA2890110A patent/CA2890110C/en active Active
- 2013-11-01 AU AU2013337651A patent/AU2013337651B2/en active Active
- 2013-11-01 BR BR122019025681-0A patent/BR122019025681B1/pt active IP Right Grant
- 2013-11-01 KR KR1020207015879A patent/KR102315098B1/ko active Active
- 2013-11-01 CN CN201380056620.0A patent/CN104769112A/zh active Pending
- 2013-11-01 RU RU2019143431A patent/RU2019143431A/ru unknown
-
2015
- 2015-04-27 MX MX2019002498A patent/MX2019002498A/es unknown
- 2015-04-30 US US14/701,199 patent/US9447395B2/en active Active
- 2015-06-10 US US14/735,603 patent/US9376669B2/en active Active
-
2016
- 2016-05-17 US US15/156,829 patent/US9487768B2/en active Active
- 2016-05-17 US US15/156,806 patent/US9464285B2/en active Active
- 2016-09-20 US US15/270,469 patent/US9657282B2/en active Active
-
2017
- 2017-04-13 US US15/487,088 patent/US9758797B2/en active Active
- 2017-08-07 US US15/670,639 patent/US10415060B2/en active Active
-
2018
- 2018-04-06 JP JP2018073677A patent/JP6793146B2/ja active Active
- 2018-04-06 JP JP2018073676A patent/JP6890565B2/ja active Active
- 2018-11-16 AU AU2018264115A patent/AU2018264115B2/en active Active
-
2019
- 2019-07-26 US US16/523,558 patent/US10590437B2/en active Active
- 2019-10-16 US US16/654,536 patent/US10752917B2/en active Active
- 2019-10-16 US US16/654,532 patent/US11339409B2/en active Active
- 2019-10-16 US US16/654,726 patent/US11339410B2/en active Active
- 2019-10-17 US US16/655,766 patent/US10767195B2/en active Active
- 2019-10-17 US US16/655,760 patent/US11332758B2/en active Active
- 2019-10-17 US US16/655,744 patent/US10724053B2/en active Active
- 2019-10-18 US US16/657,325 patent/US10752919B2/en active Active
- 2019-10-18 US US16/657,321 patent/US10752918B2/en active Active
- 2019-10-18 US US16/657,318 patent/US11332759B2/en active Active
-
2020
- 2020-06-25 US US16/912,321 patent/US12006508B2/en active Active
-
2021
- 2021-02-24 JP JP2021027831A patent/JP7436406B2/ja active Active
- 2021-10-15 AU AU2021250972A patent/AU2021250972A1/en not_active Abandoned
-
2022
- 2022-04-12 US US17/718,668 patent/US20220243228A1/en not_active Abandoned
-
2024
- 2024-02-08 JP JP2024018042A patent/JP2024056815A/ja active Pending
-
2025
- 2025-08-22 US US19/307,835 patent/US20260078413A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534817A5 (enExample) | ||
| JP2024001075A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2020510439A5 (enExample) | ||
| JP2019524149A5 (enExample) | ||
| JP2018534950A5 (enExample) | ||
| JP2020524998A5 (enExample) | ||
| JP2020511970A5 (enExample) | ||
| AU2016341919A1 (en) | CRISPR/CAS-related methods and compositions for treating hepatitis b virus | |
| JP2019508051A5 (enExample) | ||
| JP2020518276A5 (enExample) | ||
| RU2020104969A (ru) | Способы и продукты для получения и доставки нуклеиновых кислот | |
| CA2981508A1 (en) | Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy | |
| JP2019516680A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| IL310721B2 (en) | Nucleobase editors and uses thereof | |
| CN108350454A (zh) | 等位基因选择性基因编辑及其用途 | |
| CN108603192A (zh) | 用于调节潜伏的病毒转录的组合物和方法 | |
| US11072782B2 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
| JP2016500262A5 (enExample) | ||
| BR112015022507A2 (pt) | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados | |
| JP2015517803A5 (enExample) | ||
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| Gokcumen et al. | Refinement of primate copy number variation hotspots identifies candidate genomic regions evolving under positive selection | |
| JP2017510293A5 (enExample) |